Medicare Now Covers Oncotype DX Testing Oncotype DX is a genomic test that can help predict near- and long-term outcomes in prostate cancer. About half of all men diagnosed with prostate cancer could be treated with active surveillance for a period of time. The Oncotype DX test is a genomic test that can help in determining the aggressiveness of a prostate cancer case and it’s likelihood of recurrence after treatment. “More than 220,000 men are diagnosed with prostate cancer each year in the United States alone. The Medicare coverage decision extends reimbursement for Oncotype DX testing to prostate cancer patients defined as low- and very low-risk by the National Comprehensive Cancer Network (NCCN), who are eligible based on clinical and pathological factors such as prostate-specific antigen (PSA) and Gleason score.” The effective date for Medicare coverage will be after the 45-day notice period according to Palmetto GBA’s process. This should be sometime near the end of September 2015. Prostate Cancer’s Enigma Science is learning more about prostate cancer all of the time, but there still are many unknowns. With more than 20 different varieties of prostate cancer, the biggest challenge is determining which are the aggressive types that claim the lives of […] read more 
Medicare Approves New Tool for Prostate Cancer Recurrence Assessment
Medicare Now Covers Oncotype DX Testing Oncotype DX is a genomic test that can help predict near- and long-term outcomes in prostate cancer. About half of all men diagnosed with prostate cancer could be treated with active surveillance for a period of time. The Oncotype DX test is a genomic test that can help in determining the aggressiveness of a prostate cancer case and it’s likelihood of recurrence after treatment. “More than 220,000 men are diagnosed with prostate cancer each year in the United States alone. The Medicare coverage decision extends reimbursement for Oncotype DX testing to prostate cancer patients defined as low- and very low-risk by the National Comprehensive Cancer Network (NCCN), who are eligible based on clinical and pathological factors such as prostate-specific antigen (PSA) and Gleason score.” The effective date for Medicare coverage will be after the 45-day notice period according to Palmetto GBA’s process. This should be sometime near the end of September 2015. Prostate Cancer’s Enigma Science is learning more about prostate cancer all of the time, but there still are many unknowns. With more than 20 different varieties of prostate cancer, the biggest challenge is determining which are the aggressive types that claim the lives of […] read more How Spy Thriller Author Vince Flynn Succumbed to a Silent Killer
Spy Thriller Author Vince Flynn Dead at Age 47 – of Prostate Cancer! by Robert Warren Hess We learned last week that espionage thriller author Vince Flynn died on June 19, 2013, of prostate cancer at age 47. News reports tell us that Flynn was diagnosed in 2010 at age 43 with Stage 3 prostate cancer. Flynn wrote the Mitch Rapp novels about the CIA, three of which reached the Number 2 slot on USA Today’s list of best sellers. Flynn’s diagnosis and death highlight several key points that were made by two doctors on Fox New’s Sunday morning medical show, Housecall . . . Prostate cancer is not an old man’s disease Prostate cancers that appear early generally are aggressive (30,000 men die every year from prostate cancer) It’s critical to get a baseline PSA test at 35 and watch for any changes from one year to the next How to Make Your Prostate Cancer Risk Visible The best early indicator of prostate cancer is the PSA (prostate specific antigen) test. The PSA test isn’t perfect, but it is a good indicator, especially if you track your PSA’s trend over time. A simple way to do this is with […] read more Donate to PCAP
Simply click the Donate Now button below to visit our site at the Network for Good. . .
Follow PCAP
Follow Pony Express
RSS Newsletter
If you would like to stay updated with all of our latest news please enter your e-mail address here.